At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
TAS-102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing Regimen
In Brief
A Phase 1 clinical trial evaluating TAS-102 and Irinotecan for Gastric Adenocarcinoma and GastroEsophageal Cancer. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma, GastroEsophageal Cancer
CountriesUnited States
CollaboratorsTaiho Pharmaceutical Co., Ltd.
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedAug 2019
Primary CompletionJul 2021
Study CompletionJul 2022
TodayJul 2026
First PostedAug 30, 2019
Enrollment StartAug 26, 2019
Primary CompletionJul 14, 2021
Study CompletionJul 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.8 years ago
Interventions
TAS-102drug
Given PO
Irinotecandrug
Given IV